Earlier Detection of Organ Rejection
CAP review outlines how donor-derived DNA assays can support earlier, less invasive detection of graft injury
Clinical Scorecard: Earlier Detection of Organ Rejection
At a Glance
| Category | Detail |
|---|
| Condition | Organ transplant rejection |
| Key Mechanisms | Detection of donor-derived cell-free DNA (dd-cfDNA) as a marker of graft health |
| Target Population | Solid organ transplant recipients, particularly kidney and heart transplant patients |
| Care Setting | Transplant clinics and laboratories |
Key Highlights
- dd-cfDNA testing offers noninvasive and sensitive detection of graft injury
- Rising dd-cfDNA levels can indicate acute rejection before serum chemistries or biopsy changes
- Next-generation sequencing and droplet digital PCR are the main analytical approaches
- Clinical applications are most established in kidney and heart transplantation
- dd-cfDNA may reduce unnecessary biopsies and improve monitoring strategies
Guideline-Based Recommendations
Diagnosis
- Measure serial dd-cfDNA in cases of graft dysfunction to assess for rejection
Management
- Incorporate dd-cfDNA into surveillance strategies for heart transplant patients
Monitoring & Follow-up
- Utilize dd-cfDNA for dynamic monitoring of graft health
Risks
- Emerging roles in liver and lung transplantation remain less definitive
Patient & Prescribing Data
Solid organ transplant recipients, especially those with graft dysfunction
dd-cfDNA testing can guide personalized surveillance and reduce invasive procedures
Clinical Best Practices
- Implement dd-cfDNA testing as part of routine transplant monitoring
- Standardize assays for more reliable molecular monitoring
- Utilize dd-cfDNA levels to differentiate between active rejection and stable graft function
References
